Interferon therapy for lymphoproliferative disorders.
Roth
M S
MS
Bunn
P A
PA
Foon
K A
KA
D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D000951:Antigens, Neoplasm / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use; D007372:Interferons / Q000494:pharmacology / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000628:therapy*; D009101:Multiple Myeloma / Q000628:therapy; D009857:Oncogenes / Q000187:drug effects; D011994:Recombinant Proteins; D013920:Thrombocythemia, Essential / Q000628:therapy
D000951:Antigens, Neoplasm; D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins; D007372:Interferons